Another addition to kidney disease prevention

Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. 

Based on pleitropic effects of GLP-1 agonists as a drug class, the results are not surprising and serve as a welcome addition to the armamentarium of ever increasing diabetic kidney disease drugs 

https://www.nejm.org/doi/full/10.1056/NEJMoa2403347